ArticleProceedings of the National Academy of Sciences of the United States of America2013

Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.

Janani Varadarajan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.